Effect of Premedication with Ibuprofen and Meloxicam on the efficacy of Inferior Alveolar Nerve Block in Irreversible Pulpitis

Authors
Dr Suman Lamba¹, Dr Udaya Kumar Palani Swamy², Dr Mamta Kaushik³, Dr Pallavi Y Reddy⁴, Dr Pavan Kumar⁵
Corresponding author
Dr Suman Lamba
KIST Medical College, GPO Box: 14142, Mahalaxmi Municipality, Ward No. 1, Lalitpur, NEPAL
Email: dr.sumanlamba14@gmail.com

Abstract
Pain relief in irreversible pulpitis cases with inferior alveolar nerve block is difficult, more-so in the case of mandibular molars. The present study evaluated the effect of premedication with non-steroidal anti-inflammatory drugs on local anaesthesia during endodontic therapy. In a prospective, randomised, double blinded clinical trial, 75 patients (25 per group) with symptomatic irreversible pulpitis were selected. They were given either placebo, 600 mg ibuprofen, or 7.5mg meloxicam an hour before local anaesthesia. Each participant recorded their pain score on a 10 centimetre visual analogue scale four times during the procedure. Pain was recorded: 1) before taking the analgesic, 2) 15 minutes after anaesthesia in response to an electric pulp test, 3) during access cavity preparation and 4) during biomechanical preparation. No or mild pain at any stage was reported as success. Data were analysed by the Kruskal-Wallis and one way analysis of variance tests. Ibuprofen and meloxicam showed significantly better results than placebo (p<0.05). The success rates were 92%, 88% and 60% for ibuprofen, meloxicam and placebo, respectively. There was no significant difference between ibuprofen and meloxicam (p>0.05). The study concludes premedication with ibuprofen and meloxicam significantly enhances the effectiveness of local anaesthesia in patients with irreversible pulpitis.

Keywords: Anaesthesia, inferior alveolar nerve block, irreversible pulpitis, placebo, premedication.

Introduction
Pain is the principal reason for seeking emergency endodontic treatment. For a successful endodontic treatment, absolute pain relief is an essential prerequisite(¹). Local anaesthesia is considered to be the major modality for dental pain control. For mandibular molars, inferior alveolar nerve block (IANB) is the most accepted method of local anaesthesia. However, it often fails to provide adequate pain relief. Several articles have reported the success rate of 75-90 % with inferior alveolar nerve block for uninfamed pulp(²,³). The success rate further declines when the pulp is inflamed. The presence of pulpal inflammation has been reported to cause inferior alveolar nerve block failure in approximately 30%-45% of cases(⁴). Hence, some researchers have suggested reducing the pulpal inflammation before injecting anaesthesia to make it more effective(⁵). For dental pain, non-steroidal anti-inflammatory drugs (NSAIDs) have a long history of clinical use. Their over-the-counter availability
and efficacy in relieving pain and fever makes them popular drugs. Additionally, they have a low side effect profile at therapeutic doses. NSAIDs block the cyclo-oxygenase enzyme, thereby reducing prostaglandins. This in turn, results in lower levels of inflammation. Numerous studies have found ibuprofen to be effective in relieving dental pain at various dosages, especially at doses of 600–800 mg. However, according to Aggarwal V et al, neither ibuprofen nor ketorolac caused any improvement in the success of pulpal anaesthesia. So, the present study was aimed at reducing the confusion amongst endodontists about whether or not to use premedication with IANB.

In dentistry, there are rather few studies concerning the use of meloxicam and even fewer in endodontics. As meloxicam is a selective COX-2 inhibitor, it causes relatively less gastro-intestinal (GI) upset compared to other NSAIDs. It is widely used in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other rheumatologic conditions. The current study was performed to compare the effect of placebo and premedication with ibuprofen and meloxicam, on the success of inferior alveolar nerve block in patients having symptomatic irreversible pulpititis.

**Materials and Methods**

**Patient selection:** This study was a randomised, double-blinded, placebo-controlled clinical trial focussing on pre-treatment oral administration of the NSAIDs ibuprofen (Brufen 600 mg, Abbott India Ltd., India) and meloxicam (Melflam 7.5 mg, Cipla Ltd., India). Endodontic pain was evaluated before and during endodontic treatment. Ethical clearance was taken from the Institutional Ethical Committee of Army College of Dental Sciences, Secunderabad, India. The study protocol was duly approved by the committee. Out of 83 patients clinically diagnosed with irreversible pulpititis, 75 were randomly selected to participate in the study. The participants were informed about the risks and benefits of the study, in detail. Written informed consent was obtained from each subject to participate in the study.

**Randomisation Method**

The clinical diagnosis of symptomatic irreversible pulpititis was given to patients exhibiting sharp or dull, intermittent or spontaneous pain in a mandibular molar of either side. The diagnosis was confirmed by a positive response to an electric pulp tester (Parkell, Inc., Edgewood, NY). Each participant was asked to complete a baseline 10 cm VAS and was allocated a random number. They were then asked to pick an envelope from a box for their allocation to groups. The opaque envelopes contained group codes, namely I, II, III. The drugs were kept in three identical coded containers in the form of capsules; of the same size and colour. All participants were given a capsule one hour before initiating the treatment; by a trained assistant who was blinded to the experiment. The capsules contained either a placebo of lactose powder (group I), 600 mg ibuprofen (group II), or 7.5 mg meloxicam (group III). Only a single dose of analgesic was administered before treatment. The patient, the assistant dispensing medicines and the principal operator were all unaware of the codes until the completion of the study.

**Clinical procedure**

VAS scores were recorded on a 10 cm scale and divided into four categories. No pain corresponded to 0 reading, mild pain >0 to less than equal to 3,
moderate pain was defined as being >3 and less than equal to 7 and severe pain was defined as >7. Pain was recorded four times during the entire procedure. First reading for pain was made before giving the placebo/premedication. Inferior alveolar nerve block was then given one hour later. Fifteen minutes after anaesthesia, a second reading was made in response to an electric pulp test. The third reading was made during access cavity preparation and fourth during root canal instrumentation.

Disposable 5 ml syringe and 27 gauge 1¼ inch needle were used to administer local anaesthetic. The operator performed blood aspiration before IANB was administered. If the aspiration was negative, then the anaesthetic solution, 1.8 ml of 2% lignocaine with 1:80,000 adrenaline (Xicaine, ICPA Health Products Ltd., India) was injected in each patient at a rate of 1ml per minute. Fifteen minutes after anaesthesia, patients were asked for subjective symptoms. If the patient did not report with profound lip anaesthesia, then IANB was considered a failure and patient was excluded from the study. However, all 75 patients in the present study reported lip numbness so none of them were excluded. After this, access cavity preparation was started and patients were asked to rate any pain experience. No or mild pain were classified as success, whereas moderate and severe pain were classified as failure of anaesthesia. All patients were monitored for 48 hours following the procedure.

**Statistical analysis**

One way analysis of variance (ANOVA) test was used to compare the data between the three groups. Comparison between groups at different steps was carried out using Kruskal-Wallis test. The data were analysed using the software SPSS version 21.0. The comparisons were considered significant if P-value was less than 0.05.

**Results**

No patients reported with any untoward event within 48 hours. No significant differences were found in the age and sex among the patients in the three groups (Table 1). Significant difference was found between the placebo and premedication groups but no significant difference was found between the ibuprofen and meloxicam groups (P-value >0.05). The P-value was 0.001 fifteen minutes after anaesthesia, 0.001 during access preparation and 0.01 during instrumentation being <0.05 at all steps and thus statistically significant (Table 2). On the basis of these findings, null hypothesis was rejected. Overall success rates for the placebo, ibuprofen and meloxicam groups were observed to be 60%, 92% and 88% respectively. The difference can be clearly appreciated in Fig. 1. Thus, according to the present study, the use of premedication before anaesthesia is recommended in irreversible pulpitis cases.

**Table 1** Comparison of age, sex and baseline VAS scores between the groups (mean±SD)

| Group          | Placebo     | Ibuprofen  | Meloxicam  | Total       | P-value*   |
|----------------|-------------|------------|------------|-------------|------------|
| Age (years) (mean±SD) | 34.12±11.11 | 32.68±9.69 | 36.56±10.57 | 34.45±10.45 | 0.421      |
| Sex (Female: Male) | 12:13       | 11:14      | 11:14      | 34:41       | 0.950      |
| Baseline VAS score (mean±SD) | 7.08±1.41   | 7.36±1.38  | 7.60±1.50  | 7.35±1.43   | 0.442      |

*P-value <0.05 : statistically significant
†VAS: Visual analogue scale
‡SD: Standard deviation

**Table 2** Comparison of mean VAS scores before anaesthesia and steps during the procedure (mean±SD)

| Group                      | Placebo   | Ibuprofen | Meloxicam | P-value |
|----------------------------|-----------|-----------|-----------|---------|
| Before anaesthesia (mean±SD) | 7.08±1.41 | 7.36±1.38 | 7.60±1.50 | 0.442   |
| 15 mins after anaesthesia  | 2.04±1.17 | 0.84±0.80 | 1.04±0.79 | 0.001   |
| During access preparation  | 2.44±1.55 | 0.96±1.2  | 0.88±1.2  | 0.001   |
| During instrumentation     | 2.4±1.41  | 0.8±0.86  | 1.08±1.15 | 0.01    |
Discussion

The present study showed that premedication with NSAIDs (ibuprofen and meloxicam) notably improves the success rate of inferior alveolar nerve block in irreversible pulpitis cases. The age and sex of the patients were not significantly different in the three groups and so, did not affect the study results. Pain is a highly subjective experience and can be influenced by numerous factors. These include physical, psychological, behavioural and cultural factors. So, it can be challenging to quantify and standardize pain across a group of individuals. Several clinical studies have used numeric and verbal self-rating scales in the past. In a critical review of nursing and health care publications, a visual analogue scale (VAS) was found to be suitable for measuring pain intensity. VAS comprises of a 100-mm line with 0 mm marking no pain and 100 mm marking maximum pain. It is highly reproducible and unaffected by gender.

On these grounds, the VAS was considered most suitable to measure intensity of pain in the present study.

In this study, 2% lignocaine with 1:80,000 epinephrine was used, being the most common local anaesthetic agent used in dentistry, with a long history of clinical success. It is also the agent used in most previous studies on the efficacy of anaesthetic techniques and solutions and allows comparison between results of these studies.

Several previous studies have proved the anti-inflammatory effects of ibuprofen and indomethacin. Seymour and Ward evaluated various doses of ibuprofen (200mg, 400mg, 600mg) for the management of post-operative dental pain, and reported better results with 600mg ibuprofen. Meloxicam has rarely been used in endodontic studies. Solis et al demonstrated that patients receiving single dose of 15 mg preoperative meloxicam had a better postoperative analgesia compared with those given 100mg of diclofenac, after third molar extractions. Being a selective COX-2 inhibitor, it has a lower side effect profile. A lack of dose-response relationship for GI adverse effects allows for a flexibility in meloxicam dosage in the 7.5-15mg range. The decreased gastrointestinal upset gives meloxicam an advantage over...
other NSAIDs as it can be used for a wider range of patients. It provides adequate analgesia and has been successfully used in systemic conditions like osteoarthritis, rheumatoid arthritis, ankylosing spondylitis etc.\(^{12}\).

Several other investigations have proved the efficacy of premedication on IANB success rates for teeth with irreversible pulpitis\(^{10,20}\). However, Aggarwal V et al\(^{11}\) in their study concluded that pre-treatment administration of ibuprofen or ketorolac did not improve the efficacy of anaesthesia. Inconsistent results in different studies could be attributed to variable methodology or operator-related factors.

In the current investigation, the overall success rates for the placebo, ibuprofen and meloxicam groups were 60%, 92% and 88% respectively. The current study suggests that combinations of analgesics are not required and that the use of only one anti-inflammatory drug is sufficient enough to produce adequate analgesia.

Although premedication with NSAIDs increased the efficacy of inferior alveolar nerve block, none of the drugs succeeded to produce 100% success. Therefore, we should also be prepared to use supplementary anaesthetic techniques to provide the patient with a painless experience during endodontic therapy.

**Conclusion**

The present study concludes that the use of NSAID premedication increases the efficacy of local anaesthesia in patients with irreversible pulpitis. However, to reach a consensus amongst dentists about whether to use or not to use premedication, more extensive studies need to be performed in future.

**Acknowledgements**

The current study is attributed to the Department of Conservative Dentistry and Endodontology, Army College of Dental Sciences, Secunderabad. We thank ACDS for providing the platform and financial support for conducting the study.

We heartily thank Dr. Amita Pradhan and Dr. Sijan Poudyal for their valuable contribution in the statistical analysis. The authors deny any conflicts of interest regarding the present study.

**References**

1. O’Keefe EM. Pain in endodontic therapy: Preliminary study. J Endod 1976;2:315-19.
2. Hargreaves KM. Neurochemical factors in injury and inflammation in orofacial tissues. In: Lavigne G, Lund J, Sessle B, Dubner R, eds. Orofacial pain: Basic sciences to clinical management. Chicago: Quintessence, 2001;45-52.
3. Jastak J, Yagiela J, Donaldson D. Local anaesthetic of the oral cavity. Philadelphia: Sanders, 1995:1-339.
4. Potočnik I, Bajrovič F. Failure of inferior alveolar nerve block in endodontics. Endod Dent Traumatol 1999;15:247–51.
5. Ingle JI, Walton RE, Malamed SF. Preparation for endodontic treatment. In: Ingle JI, Bakland LK, eds. Endodontics. 5th edn. Hamilton: BC Decker, 2002;385.
6. Trowbridge H, Emling R. Chemical mediators of the vascular response. In: Inflammation: a review of the process, 5th edn. Chicago: Quintessence, 1997:33.
7. Dionne RA, Campbell RA, Cooper SA, Hall DL, Buckingham B. Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine. J Clin Pharmacol 1983;23:37–43.
8. Cooper SA. Five studies on ibuprofen for postsurgical dental pain. Am J Med 1984;77:70 –7.
9. Dionne RA, Cooper SA. Evaluation of preoperative ibuprofen for postoperative pain after removal of third molars. Oral Surg Oral Med Oral Pathol 1978; 45:851–6.
10. Parirokh M, Ashouri R, Rekabi AR, Nakhaee N, Pardakhti A, Askarifard S, Abbott PV. The effect of premedication with
ibuprofen and indomethacin on the success of inferior alveolar nerve block for teeth with irreversible pulpitis. J Endod 2010; 36:1450-4.
11. Aggarwal V, Singla M, Debipada K. Comparative evaluation of effect of preoperative oral medication of ibuprofen and ketorolac on anesthetic efficacy of inferior alveolar nerve block with lidocaine in patients with irreversible pulpitis: A prospective double-blind randomized clinical trial. J Endod 2010;102:399-403.
12. M. Del Tacca, R. Colucci, M. Fornai, C. Blandizzi. Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug. Clin Drug Invest 2002;22.
13. Sayeed Attar, Walter R. Bowles, Michael K. Baisden. Evaluation of pre-treatment analgesia and endodontic treatment for postoperative endodontic pain. J Endod 2008;34:652-5.
14. Coll AM, Ameen JR, Moseley LG. Reported pain after day surgery: a critical literature review. J AdvNurs 2004;46:53–65.
15. Goddard G, Karibe H, McNeill C. Reproducibility of visual analog scale (VAS) pain scores to mechanical pressure. Cranio 2004;22:250–6.
16. Bigby J, Reader A, Nusstein J, Beck M. Anaesthetic efficacy of lidocaine/meperidine for inferior alveolar nerve blocks in patients with irreversible pulpitis. J Endod 2007;33:7-10.10
17. McLean C, Reader A, Beck M, Meryers WJ. An evaluation of 4% prilocaine and 3% meperidine compared with 2% lidocaine for IANB. J Endod 1993;19:146-50.
18. Seymour R, Ward P. Evaluation of different dosages of soluble ibuprofen and ibuprofen tablets in postoperative dental pain. Br J Oral MaxillofacSurg 1996;34:110-4.
19. Orozco-Solís M, García-Ávalos Y, Pichardo Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA. Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery. Med Oral Patol Oral Cir Bucal 2016;21:e127–e134.
20. Modaresi J, Dianat O, Mozayeni MA. The efficacy of ibuprofen, acetaminophen-codeine, and placebo premedication therapy on the depth of anaesthesia during treatment of inflamed teeth. Oral Surg Oral Med Oral Pathol Oral RadiolEndod 2006;102:399-403.